{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:58:42Z","timestamp":1790773122814,"version":"4.1.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Portal vein tumor thrombosis (PVTT) is one of the most clinically consequential manifestations of advanced hepatocellular carcinoma (HCC). It reflects aggressive tumor biology, compromises portal venous inflow, and reduces the therapeutic window for locoregional intervention. Historically, macroscopic portal vein invasion generally placed patients within advanced-stage treatment pathways, in which systemic therapy constituted the standard treatment backbone and curative-intent approaches were applicable only to selected patients. This paradigm has now shifted. In recent years, the management of unresectable HCC has been reshaped by immune-based systemic therapy, more active tyrosine kinase inhibitor-based combinations, hepatic arterial infusion chemotherapy (HAIC), selective transarterial therapies, thrombus-directed radiotherapy, and increasingly standardized multidisciplinary conversion strategies. Consequently, a subset of patients with liver-dominant HCC and PVTT can now be downstaged to radical resection or other definitive local treatment, particularly when liver function is preserved and therapy is initiated before irreversible hepatic decompensation develops. This review summarizes recent advances in the diagnosis and classification of PVTT, the biological and technical rationale for conversion therapy, and the evolving evidence for systemic therapy, HAIC, transarterial chemoembolization (TACE), radiotherapy, triple-modality treatment, salvage surgery, and postoperative management. It also highlights key limitations, including the predominance of retrospective East Asian cohorts, heterogeneity in PVTT classification and treatment protocols, uncertainty regarding the optimal timing of surgery, and the absence of validated biomarkers for selecting patients most likely to benefit from aggressive multimodality treatment. Overall, the available evidence supports integrating response-guided multidisciplinary strategies into established evidence-based treatment frameworks for carefully selected patients. Even so, conversion therapy for HCC with PVTT remains an evidence-evolving strategy that should be applied with careful patient selection, disciplined treatment sequencing, and substantial institutional expertise rather than adopted as a universal standard of care.<\/jats:p>","DOI":"10.3389\/fonc.2026.1925747","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:14:20Z","timestamp":1790770460000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Recent advances in conversion therapy for hepatocellular carcinoma with portal vein tumor thrombosis"],"prefix":"10.3389","volume":"16","author":[{"given":"Panpan","family":"Xie","sequence":"first","affiliation":[{"name":"Department of General Surgery, Changyi People\u2019s Hospital","place":["Weifang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfang","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Changyi People\u2019s Hospital","place":["Weifang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Changyi People\u2019s Hospital","place":["Weifang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Qilu Hospital of Shandong University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengguo","family":"Jian","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Changyi People\u2019s Hospital","place":["Weifang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s10585-022-10188-1","article-title":"Portal vein tumor thrombosis in hepatocellular carcinoma: molecular mechanism and therapy","volume":"40","author":"Zhou","year":"2023","journal-title":"Clin Exp Metastasis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i32.7289","article-title":"Management of hepatocellular carcinoma with portal vein tumor thrombosis: Review and update at 2016","volume":"22","author":"Chan","year":"2016","journal-title":"World J Gastroenterol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma","volume":"82","author":"Sangro","year":"2025","journal-title":"J Hepatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02745","article-title":"Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update","volume":"42","author":"Gordan","year":"2024","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou Alfa","year":"2022","journal-title":"NEJM Evid"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(25)00059-7","article-title":"Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial","volume":"10","author":"Shi","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3760\/cma.j.cn112137-20251211-03271","article-title":"Guidelines for diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus in China (2026 edition)","volume":"106","year":"2026","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2016.00075","article-title":"A review of non-operative treatments for hepatocellular carcinoma with advanced portal vein tumor thrombus","volume":"5","author":"Moriguchi","year":"2017","journal-title":"J Clin Transl Hepatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.635731","article-title":"The progress in the treatment of hepatocellular carcinoma with portal vein tumor thrombus","volume":"11","author":"Lu","year":"2021","journal-title":"Front Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1177\/15330338231159718","article-title":"The current status and future prospects for conversion therapy in the treatment of hepatocellular carcinoma","volume":"22","author":"Bai","year":"2023","journal-title":"Technol Cancer Res Treat"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1186\/s12885-024-12772-y","article-title":"Systemic conversion therapies for initially unresectable hepatocellular carcinoma: a systematic review and meta-analysis","volume":"24","author":"Xu","year":"2024","journal-title":"BMC Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.21037\/hbsn-21-328","article-title":"Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition)","volume":"11","year":"2022","journal-title":"Hepatobiliary Surg Nutr"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1073531","article-title":"Conversion therapy for advanced hepatocellular carcinoma with vascular invasion: a comprehensive review","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-23027-6","article-title":"Locoregional therapy combined with targeted therapy and immunotherapy for hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis","volume":"15","author":"Jiang","year":"2025","journal-title":"Sci Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2023.1165","article-title":"Efficacy of lenvatinib combined with anti-PD-1 antibodies plus transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a retrospective, multicenter study","volume":"56","author":"Ou","year":"2024","journal-title":"Cancer Res Treat"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1186\/s12885-025-14543-9","article-title":"Lenvatinib combined with anti-PD-1 antibodies plus locoregional treatment for initial unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a multicenter real-world study","volume":"25","author":"Chi","year":"2025","journal-title":"BMC Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1159\/000528356","article-title":"Outcomes of salvage surgery for initially unresectable hepatocellular carcinoma converted by transcatheter arterial chemoembolization combined with lenvatinib plus anti-PD-1 antibodies: a multicenter retrospective study","volume":"12","author":"Wu","year":"2023","journal-title":"Liver Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae032","article-title":"Salvage surgery for initially unresectable HCC with PVTT converted by locoregional treatment plus tyrosine kinase inhibitor and anti-PD-1 antibody","volume":"29","author":"Wang","year":"2024","journal-title":"Oncologist"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S479810","article-title":"Neoadjuvant-based triple therapy for hepatocellular carcinoma with type I\/II portal vein tumor thrombosis","volume":"11","author":"Hou","year":"2024","journal-title":"J Hepatocell Carcinoma"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02184","article-title":"Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a randomized, open-label, multicenter controlled study","volume":"37","author":"Wei","year":"2019","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18020277","article-title":"Impacts of liver resection with neoadjuvant treatment versus surgery alone in hepatocellular carcinoma with portal vein tumour thrombosis: a systematic review and meta-analysis","volume":"18","author":"Rajagopal","year":"2026","journal-title":"Cancers (Basel)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2024.0506","article-title":"Adjuvant transarterial chemoembolization with sorafenib for portal vein tumor thrombus: a randomized clinical trial","volume":"159","author":"Peng","year":"2024","journal-title":"JAMA Surg"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyag054","article-title":"Optimal duration of adjuvant targeted-immunotherapy in patients with initially unresectable hepatocellular carcinoma with portal vein tumor thrombus following successful conversion therapy","volume":"31","author":"Wang","year":"2026","journal-title":"Oncologist"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215430","article-title":"Locoregional therapies for hepatocellular carcinoma with portal vein tumor thrombosis","volume":"13","author":"Zane","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/tomography9050154","article-title":"The role of contrast-enhanced ultrasound in the detection of neoplastic portal vein thrombosis in patients with hepatocellular carcinoma","volume":"9","author":"Cerrito","year":"2023","journal-title":"Tomography"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.09090304","article-title":"Differentiation of malignant thrombus from bland thrombus of the portal vein in patients with hepatocellular carcinoma: application of diffusion-weighted MR imaging","volume":"254","author":"Catalano","year":"2010","journal-title":"Radiology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.5582\/bst.2024.01394","article-title":"Chinese expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition)","volume":"18","author":"Tang","year":"2024","journal-title":"Biosci Trends"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.21037\/atm-20-6063","article-title":"Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients","volume":"8","author":"Chen","year":"2020","journal-title":"Ann Transl Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.211545","article-title":"Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib for hepatocellular carcinoma with major portal vein tumor thrombosis: a randomized trial","volume":"303","author":"Zheng","year":"2022","journal-title":"Radiology"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01963","article-title":"Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: a biomolecular exploratory, randomized, phase III trial (FOHAIC-1)","volume":"40","author":"Lyu","year":"2022","journal-title":"J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/jgh.16088","article-title":"Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib alone for advanced hepatocellular carcinoma: a systematic review and meta-analysis","volume":"38","author":"Long","year":"2023","journal-title":"J Gastroenterol Hepatol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.821599","article-title":"TACE plus lenvatinib versus TACE plus sorafenib for unresectable hepatocellular carcinoma with portal vein tumor thrombus: a prospective cohort study","volume":"11","author":"Ding","year":"2021","journal-title":"Front Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00392","article-title":"Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase III, randomized clinical trial (LAUNCH)","volume":"41","author":"Peng","year":"2023","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.5847","article-title":"Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial","volume":"4","author":"Yoon","year":"2018","journal-title":"JAMA Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2017.11.013","article-title":"Comparison of radiation therapy modalities for hepatocellular carcinoma with portal vein thrombosis: a meta-analysis and systematic review","volume":"129","author":"Rim","year":"2018","journal-title":"Radiother Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1159\/000540857","article-title":"Chinese expert consensus on the combination of targeted therapy and immunotherapy with locoregional therapy for intermediate\/advanced hepatocellular carcinoma","volume":"13","author":"Bi","year":"2024","journal-title":"Liver Cancer"},{"key":"B42","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/clinchem\/hvad168","article-title":"Circulating tumor DNA clinical applications in hepatocellular carcinoma: current trends and future perspectives","volume":"70","author":"Chidambaranathan-Reghupaty","year":"2024","journal-title":"Clin Chem"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222313073","article-title":"Circulating tumor cells in hepatocellular carcinoma: a comprehensive review and critical appraisal","volume":"22","author":"Espejo Cruz","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1508028","article-title":"Prognostic significance of early alpha fetoprotein and des-gamma carboxy prothrombin responses in unresectable hepatocellular carcinoma patients undergoing triple combination therapy","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.13105","article-title":"Serial circulating tumor DNA to predict early recurrence in patients with hepatocellular carcinoma: a prospective study","volume":"16","author":"Zhu","year":"2022","journal-title":"Mol Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S513696","article-title":"MRI radiomics to predict early treatment response to TACE combined with lenvatinib plus a PD-1 inhibitor for hepatocellular carcinoma with portal vein tumor thrombus","volume":"12","author":"Lu","year":"2025","journal-title":"J Hepatocell Carcinoma"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32740","article-title":"The liver cancer immune microenvironment: therapeutic implications for hepatocellular carcinoma","volume":"77","author":"Donne","year":"2023","journal-title":"Hepatology"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.12.016","article-title":"Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma","volume":"82","author":"Cappuyns","year":"2025","journal-title":"J Hepatol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1925747\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:14:23Z","timestamp":1790770463000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1925747\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":48,"alternative-id":["10.3389\/fonc.2026.1925747"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1925747","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"article-number":"1925747"}}